



ECNP  
Research &  
Scholarship  
Foundation

Annual Report  
2023

# ECNP Research and Scholarship Foundation

## Annual Report 2023

1. About ECNP R&S	3
Objectives	3
Board	3
2. Activities 2023	4
Scientific and educational meetings	4
Awards	4
Other major initiatives	5
3. Financial Overview	6
Financial statements	6
4. Future Outlook	8



The ECNP Research and Scholarship Foundation is a public-interest-serving entity (*algemeen nut beogende instelling* – ANBI) under Dutch tax law.

# 1. About ECNP R&S

The ECNP Research and Scholarship Foundation (ECNP R&S) is an independent foundation that exists to promote high-quality experimental and clinical research and education in applied and translational neuroscience, with a view to stimulating the development of better treatments for those suffering disorders of the brain.

The object of the Foundation is to create a framework for the organisation of the annual congresses of ECNP. It is a non-profit making body.

**Address:** Daltonlaan 400, 3584 BK Utrecht, The Netherlands

**E-mail:** secretariat@ecnp.eu

**Website:** <https://www.ecnp.eu>

**RSIN:** 807967087

**Dutch Chamber of Commerce number:** 41215196

**Dutch TAX number:** NL807967087B01

**ANBI:** The ECNP Research and Scholarship Foundation is a public-interest-serving entity (*algemeen nut beogende instelling* – ANBI) under Dutch tax law.

## Objectives

ECNP R&S is an independent foundation that exists to promote high-quality experimental and clinical research and education in applied and translational neuroscience, with a view to stimulating the development of better treatments for those suffering disorders of the brain.

The object of the Foundation is to create a framework for the organisation of the annual congresses of ECNP. It is a non-profit making body.

## Board

Martien Kas  
*President*  
The Netherlands

Brenda Penninx  
*Treasurer*  
The Netherlands

Suzanne Dickson  
*Secretary*  
Sweden

The members of the board receive no remuneration for their role.

-----  
Alexander Schubert  
*Executive Director*  
The Netherlands

## 2. Activities 2023

To execute its mission to support European applied and translational neuroscience, ECNP R&S performs a number of activities annually, focusing especially on stimulating research, sponsoring education and raising awareness.

In 2023 the following programmes were delivered:

### Scientific and educational meetings

- **ECNP Workshop for Early Career Scientists in Europe**

16-19 March 2023 – Nice, France

The Workshop offers 100 European early career scientists three days of intense interaction with research leaders discussing the latest advances and perspectives in translational neuroscience. Funded by ECNP R&S.

- **ECNP New Frontiers Meeting: Psychedelics**

19-20 March 2023 – Nice, France

A unique platform for focused, high-level exchange between scientists, industry leaders and regulators at the intersection of research science and new treatment development. The 2023 meeting explored topics in the molecular mechanisms, pharmacology, neuroimaging, psychological variables, and clinical trial challenges of psychedelic medicines, as well as regulatory requirements and patient perspectives. Registration and catering was funded by ECNP R&S.

- **ECNP Workshop on Clinical Research Methods**

8-10 November 2023 – Barcelona, Spain

The Workshop offers 50 European early career scientists three days of training on research methodology and critical approaches to the scientific literature for early career scientists. Tuition, registration, accommodation and catering was funded by ECNP R&S.

### Awards

- **ECNP Downloads Prize**

Awarded to the most-downloaded research paper in the ECNP journal, *Neuroscience Applied* (NSA) in the preceding two years, the award recognises and encourages impactful original research. Supported by ECNP R&S.

Winner 2023: Eline C.H.M. Haijen et al., 'Microdosing with psychedelics to self-medicate for ADHD symptoms in adults: A prospective naturalistic study, *Neuroscience Applied* 1, 2022, 101012.

- **ECNP Negative Results Prize in Clinical Neuroscience**

Awarded to papers that have made exceptional contributions to CNS treatment science by publishing clinical research with negative findings. Supported by ECNP R&S in co-operation with Cohen Veterans Bioscience.

Winner 2023: Boushra Dalile et al., 'Extruded wheat bran consumption increases serum short-chain fatty acids but does not modulate psychobiological functions in healthy men: a randomized, placebo-controlled trial', *Frontiers in Nutrition*, 9, 2022.

## Other major initiatives

- **Neuroscience-based Nomenclature (NbN)**

This international collaborative venture, led by ECNP, is working to develop a new nomenclature for psychotropic medications grounded in the latest advances in brain science. Unique in its aims and unprecedented in its scope, in 2023 the initiative's NbN app and NbN-ca app for child and adolescent treatments reached over 180,000 downloads worldwide, with translations in French, Spanish and Chinese, and Portuguese and patient-and-family versions in preparation. Funded by ECNP R&S.

- ***Neuroscience Applied***

This fully open-access scientific journal targets the intersection between neuroscience, applications and new treatment horizons, and features original basic, clinical and integrative research with translational relevance for mental health. Focusing especially on neuroscientific approaches to brain disorders, it encompasses mechanisms of disorders, biological, psychological and social treatments, prevention and policies. The journal is fully owned by ECNP R&S.

## 3. Financial Overview

ECNP R&S's policy is at all times to handle its disposable assets in a responsible and sustainable manner. The principles of this policy are:

- Proactive tax and regulatory compliance
- Strict observance of the requirements of ANBI ('algemeen nut beogende instelling' = public-interest-service entity) status
- Capital preservation – at the levels agreed with the Dutch tax authorities
- Budgetary discipline
- Ongoing diversification of the revenue base

To give substance to this, ECNP R&S invests in securities through an established asset manager using a defensive policy. The goal is to preserve wealth, to ensure the College can continue to perform its public-good activities, not to maximise return.

### Financial statements

#### Balance sheet as at 31 December 2023

(after appropriation of profit/losses)

	31-12-2023		31-12-2022	
	€	€	€	€
<b>ASSETS</b>				
<b>FIXED ASSETS</b>				
<b>Financial fixed assets</b>				
Securities		11,018,368		11,018,368
<b>CURRENT ASSETS</b>				
<b>Accounts receivable</b>				
Debtors	1,484		13,076	
Amounts owed by congress foundations	337,774		309,192	
Taxes	1,961		1,377	
Other accounts receivables	49,054		82,240	
		390,273		405,885
<b>Bank deposits</b>		2,481,951		2,064,730
		2,872,224		2,470,615
		<u>13,890,592</u>		<u>13,488,983</u>

	31-12-2023		31-12-2022	
	€	€	€	€
<b>EQUITY AND LIABILITIES</b>				
<b>EQUITY AND FUNDS</b>				
Other reserves		13,796,336		13,432,839
<b>CURRENT LIABILITIES</b>				
Trade creditors	14,612		31,521	
Other liabilities	79,644		24,623	
		94,256		56,144
		<u>13,890,592</u>		<u>13,488,983</u>

### Statement of income and expenditure 2023

	Balance 2023	Balance 2022
	€	€
<b>Income</b>		
Proceeds fundraising	1,090,827	696,078
Journal Neuroscience Applied	20,853	18,000
Neuroscience-based Nomenclature	24,805	24,407
Interest and similar income	15,580	-
<b>Total income</b>	<u>1,152,065</u>	<u>738,485</u>
<b>Expenses</b>		
Administration	374,038	301,137
Meetings	308,697	255,827
Journal Neuroscience Applied	23,000	29,000
Neuroscience-based Nomenclature	64,297	101,637
Other expenses	16,821	18,381
<b>Total expenses</b>	<u>786,853</u>	<u>705,982</u>
<b>Balance before financial expense</b>	<u>365,212</u>	<u>32,503</u>
Interest and similar charges	-1,715	-6,673
<b>Net result</b>	<u>363,497</u>	<u>25,830</u>
<b>Appropriation of result</b>		
Other reserves	<u>363,497</u>	<u>25,830</u>

## 4. Future Outlook

The ongoing review of ECNP R&S's purpose and strategy continues, as the College reviews its mission, where the most impactful contributions can be made, and how relevance and long-term (economic) viability can be assured. Specific issues include:

- How the landscape of European brain science is changing and how ECNP's programmes and activities should adapt to these changes.
- How technology is reshaping the ways in which science is generated, disseminated and consumed, and how ECNP should respond.
- How the organisation's activities can meet the scale of the need they are designed to serve and achieve an impact commensurate with the College's mission.
- How the organisation can fulfil its social obligation to reduce its carbon footprint and contribute to environmental preservation.

Plans are being developed to effect change and renewal in all of these areas and equip the organisation with the structures and systems necessary to meet the next 35 years of its existence. Flagship investments include a full-scale learning management system (LMS) and content library to expand the scale and reach of ECNP's educational activities and make available its significant store of scientific and learning materials.



